Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thorough QT Study of TD-4208 (Revefenacin) in Healthy Subjects
NCT02820311Phase 1Completed
- Sponsor
- Mylan
- Start
- May 2016
- Primary completion
- Jul 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of revefenacin in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Mylan. Primary endpoint: Change-from-baseline in corrected QT at 24 hours. Started May 2016; status: completed.
02
Drugs
revefenacin
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02820311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02820311.